The cutaneous and intestinal microbiome in psoriatic disease.


Journal

Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537

Informations de publication

Date de publication:
09 2020
Historique:
received: 24 05 2020
revised: 04 07 2020
accepted: 08 07 2020
pubmed: 18 7 2020
medline: 18 5 2021
entrez: 18 7 2020
Statut: ppublish

Résumé

Psoriasis (PsO) and psoriatic arthritis (PsA) are chronic immune-mediated inflammatory diseases of multifactorial etiology. In addition to genetic and environmental factors, evidence supports involvement of a dysregulated human microbiome in the pathogenesis of psoriatic disease. In particular, alterations in the composition of the microbiome, termed dysbiosis, can result in downstream proinflammatory effects in the gut, skin, and joints. Both the cutaneous and intestinal microbial populations are implicated in the pathogenesis of psoriatic disease, although exact mechanisms are unclear. Herein, we review the relationship between the human microbiome and psoriatic disease. Further insight into the functions of the microbiome may allow for greater understanding of inflammatory disease processes and identification of additional therapeutic targets.

Identifiants

pubmed: 32679247
pii: S1521-6616(20)30433-2
doi: 10.1016/j.clim.2020.108537
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

108537

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Stephanie T Le (ST)

Department of Dermatology, University of California, Davis, Sacramento, CA, United States.

Atrin Toussi (A)

Department of Dermatology, University of California, Davis, Sacramento, CA, United States; University of California, Davis, School of Medicine, Sacramento, CA, United States.

Natalia Maverakis (N)

New York University, New York City, NY, United States.

Alina I Marusina (AI)

Department of Dermatology, University of California, Davis, Sacramento, CA, United States.

Virgina R Barton (VR)

Department of Dermatology, University of California, Davis, Sacramento, CA, United States.

Alexander A Merleev (AA)

Department of Dermatology, University of California, Davis, Sacramento, CA, United States.

Guillaume Luxardi (G)

Department of Dermatology, University of California, Davis, Sacramento, CA, United States.

Siba P Raychaudhuri (SP)

Department of Dermatology, University of California, Davis, Sacramento, CA, United States; Department of Medicine, VA Medical Center, Mather, CA, USA; Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, Sacramento, CA, United States.

Emanual Maverakis (E)

Department of Dermatology, University of California, Davis, Sacramento, CA, United States. Electronic address: emaverakis@ucdavis.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH